GenePharma

pGPH1 siRNA Expression Vector Kit

A vector designed for the cloning and expression of short haipin RNA (shRNA) in mammalian cells under the control of human H1 promoter

Catalog No. E-01/F-01

User Manual

Table of Contents

I. Product Description and Background……... 1

A. siRNA and RNA interference

B. pGPH1 siRNAExpression Vectors

C. siRNA Template Design

D. Kit Components and Storage

E. Other Required Material

F. Related Products Available from GenePharma

II. Planning and Preliminary Experiments……... 6

A. siRNA Target Site Selection

B. Hairpin siRNA Template Oligonucleotide Design & Ordering

III. Using the pGPH1 siRNA Expression Vector…… 9

A. Cloning Hairpin siRNA Inserts into pGPH1

B. Transfecting pGPH1 into Mammalian Cells

IV. Troubleshooting…….……. 12

A. Positive Control Ligation

B. Using the Positive and Negative Control

C. Low *E. coli* Transformation Efficiency

D. Equal Numbers of *E. coli* Colonies from Minus- and Plus-insert Ligation Transformations

E. Poor Mammalian Cell Transfection Efficiency

V. Appendix…….…….……. 17

A. Reference

B. pGPH1 siRNA Expression Kit Specifications

C. Quality Control

D. Map of pGPH1

E. pGPH1 multiple cloning site region

F. Sequece of pGPH1

I. Product Description and Background

A. siRNA and RNA Interference

Small Interfering RNAs (siRNAs) are short, double-stranded RNA molecules that can target mRNAs with complementary sequence for degradation via a cellular process termed RNA interference (RNAi) (Elbashir 2001). Researchers in many disciplines employ RNAi to analyze gene function in mammalian cells. The siRNA used in early studies was typically prepared in vitro and transfected into cells. More recent publications feature plasmids that express functional siRNA when transfected into mammalian cells (Sui 2002, Lee 2002, Paul 2002, Paddison 2002, Brummelkamp 2002). Using siRNA expression vectors has the advantage that the expression of target genes can be reduced for weeks or even months (Brummelkamp 2002), eclipsing the 6–10 days typically observed with in vitro prepared siRNA used for transient transfection (Byrom 2002).

B. pGPH1 siRNA Expression Vectors

Mammalian promoters for siRNA expression

The pGPH1 vectors employ RNA polymerase III (pol III) promoters which generate large amounts of small RNA using relatively simple promoter and terminator sequences. GenePharma's pGPU6 siRNA Expression vector features a human U6 RNA pol III promoter, and pGPH1 contains the H1 RNA pol III promoter. These promoters are well characterized (Myslinski 2001, Kunkel 1989), and they provide high levels of constitutive expression across a variety of cell types. The terminator consists of a short stretch of uridines (usually 3–4 nt); this is compatible with the original siRNA design that terminates with a two uridine 3' overhang (Elbashir 2001).

Based on comparisons of several different RNA pol III promoters, the activities of the two promoters are likely to vary from cell type to cell type (Ilves 1996). The localization of expressed RNA is also likely to vary with cell type and with RNA pol III promoter (Ilves 1996). To optimize siRNA expression, we find it beneficial to clone hairpin siRNAs into both the pGPU6 and pGPH1 vectors and transfect them into the cells being targeted for gene knockdown. The promoter that is more effective for the siRNA and cell type will provide greater levels of gene silencing.

pGPH1 plasmid is supplied ligation-ready

The pGPH1 siRNA Expression vector is linearized with both *Bam* HI and *Bbs* I to facilitate directional cloning. They are purified to remove the digested insert so that it cannot re-ligate with the vector. This greatly increases the percentage of clones bearing the hairpin siRNA-coding insert after ligation, reducing the time and effort required to screen clones. Both pGPU6 and pGPH1 are linearized with the same restriction enzymes, so that a given hairpin siRNA insert can be subcloned into either vector using the 5' overhangs left by restriction enzyme digestion. A basic pGPH1 vector map is shown in Figure 1 on page 2; more detailed sequence information about the pGPH1 vector is available from the Technology Support of GenePharma, Inc..

http://www.genepharma.com

support@genepharma.com

Figure 1. pGPH1 siRNA expression vector map



Feature	Nucleotide position
f1 (–) origin of ss-DNA replication	21-327
HH1 promoter	653-888
T7 promoter binding site	625-648
T3 promoter binding site	998-1018
pUC origin of replication	1385-2051
Ampicillin resistance (*bla*) ORF	2203-3059

C. siRNA Template Design

Figure 2. Hairpin siRNA



The prototypical siRNA comprises two hybridized 21-mer RNA molecules with 19 complementary nucleotides and 3' terminal dinucleotide overhangs. Expression vectors with dual promoters that express the two strands of the siRNA separately can be used (Lee 2002), however, a more efficient scheme is to express a single RNA that is a 19-mer hairpin with a loop and 3' terminal uridine tract (Paddison 2002) (Figure 2). When expressed in mammalian cells, the hairpin siRNA is apparently recognized by Dicer, the nuclease responsible for activating dsRNAs for the RNAi pathway, and cleaved to form a functional siRNA (Brummelkamp 2002). For cloning into an siRNA expression vector, hairpin siRNA inserts have the advantage that only a single pair of oligonucleotides and a single ligation are needed to generate plasmid for gene silencing studies. For each target gene, design complementary 55–60 mer oligonucleotides with 5' single-stranded overhangs for ligation into the pGPH1 vectors. The oligonucleotides should encode 19-mer hairpin sequences specific to the mRNA target, a loop sequence separating the two complementary domains, and a polythymidine tract to terminate transcription (this is discussed in section II.B on page 7).

Strategy for selection of siRNA target sites

The susceptibility of siRNA target sites to siRNA-mediated gene silencing appears to be the same for both in vitro prepared siRNAs and RNA pol III-expressed siRNAs. Thus sequences that have been successfully targeted with a chemically synthesized, in vitro transcribed, or PCR-generated siRNA should also be susceptible to down-regulation with an siRNA expressed from a pGPH1 vector. If an siRNA target site has not already been identified, then we recommend that several different siRNAs be tested per gene. This can be conveniently done using in vitro prepared or chemical synthesized siRNAs (e.g. siRNAs synthesized by Genepharma, Cat No A01005). Once an effective target site is identified, oligonucleotides encoding hairpin siRNAs can be synthesized and ligated into pGPH1 siRNA Expression Vector. This significantly reduces the time and effort required to develop an effective siRNA plasmid specific to a given gene.

D. Kit Components and Storage

Each pGPH1 siRNA Expression Vector Kit includes 4 components:
• Linearized pGPH1 siRNA Expression Vector ready for ligation
• Circular, negative control pGPH1 vector that expresses a hairpin siRNA with limited homology to any known sequences in the human, mouse, and rat genomes
• human GAPDH-specific, hairpin siRNA insert that can be used as a positive control for ligation
• 1XDNA Annealing Solution to prepare annealed DNA oligonucleotides for ligation into the pGPH1 vector

E-01	F-01	Component
20 µl		pGPH1 (circular) (50 ng/ul)
	20µl	pGPH1 (linearized) (50 ng/ul)
10 µl	10 µl	pGPH1 Negative control (0.5 µg/µl)
10 µl	10 µl	GAPDH Control Insert (20 nM)
0.5 ml	0.5 ml	10×shDNA Annealing Solution

Store the pGPH1 siRNA Expression Vector Kit at –20°C (if desired the 1XDNA Annealing Solution can be stored at room temp). Properly stored kits are guaranteed for 6 months from the date received.

E. Other Required Material

Ligation and transformation

• Two complementary oligonucleotides targeting the gene of interest for RNAi (design and ordering is discussed in section II starting on page 6)
• DNA ligase, ligase reaction buffer, and competent *E. coli* cells are needed to subclone the siRNA inserts.
• Ampicillin or carbenicillin containing plates and liquid media will also be needed to propagate the plasmids.

Plasmid purification

For efficient transfection into mammalian cells it is crucial that preparations of pGPH1 be very pure.

Mammalian cell transfection reagents

The optimal mammalian cell transfection conditions including transfection agent and plasmid amount must be determined empirically.

F. Related Products Available from GenePharma

Cat. No.	Description	Package	Purification
A01005	Custom siRNA	5 OD	HPLC
A02005	Chemically modified siRNA	5 OD	HPLC
A03005	Fluorescent dye labeled siRNA	5 OD	HPLC
B01001	Negative Control siRNA	1 OD	HPLC
B02001	FITC negative control siRNA	1 OD	HPLC
B03001	Positive control siRNA	1 OD	HPLC
C-01	RNAi-Mate transfection Reagent	0.1 ml	
E-03/F-03	pGPH1/Neo	1 μg	
E-05/F-05	pGPH1/Hygro	1 μg	
E-07/F-07	pGPH1/GFP/Neo	1 μg	

吉玛基因

II. Planning and Preliminary Experiments

A. siRNA Target Site Selection

Using siRNA for gene silencing is a rapidly evolving tool in molecular biology; these instructions are based on both the current literature, and on empirical observations by scientists at GenePharma.

1. Find 21 nt sequences in the target mRNA that begin with an AA dinucleotide

Beginning with the AUG start codon of your transcript, scan for AA dinucleotide sequences. Record each AA and the 3' adjacent 19 nucleotides as potential siRNA target sites.

This strategy for choosing siRNA target sites is based on the observation by Elbashir et al. (EMBO 2001) that siRNA with 3' overhanging UU dinucleotides are the most effective. This is compatible with using RNA pol III to transcribe hairpin siRNAs because it terminates transcription at 4–6 nucleotide poly(T) tracts creating RNA molecules with a short poly(U) tail.

2. Select 2–4 target sequences

Research at GenePharma has found that typically more than half of randomly designed siRNAs provide at least a 50% reduction in target mRNA levels and approximately 1 of 4 siRNAs provide a 75–95% reduction. Choose target sites from among the sequences identified in step 1 based on the following guidelines:

• Since a 4–6 nucleotide poly(T) tract acts as a termination signal for RNA pol III, avoid stretches of ≥4T's or A's in the target sequence.

• Since some regions of mRNA may be either highly structured or bound by regulatory proteins, we generally select siRNA target sites at different positions along the length of the gene sequence. We have not seen any correlation between the position of target sites on the mRNA and siRNA potency.

• Compare the potential target sites to the appropriate genome database (human, mouse, rat, etc.) and eliminate from consideration any target sequences with more than 16–17 contiguous base pairs of homology to other coding sequences. We suggest using BLAST, which can be found on the NCBI server at: www.ncbi.nlm.nih.gov/BLAST.

• GenePharma researchers find that siRNAs with 30–50% G/C content are more active than those with a higher G/C content.

3. Negative Controls

A complete siRNA experiment should include a negative control siRNA with the same nucleotide composition as your siRNA but which lacks significant sequence homology to the genome. To design a negative control siRNA, scramble the nucleotide sequence of the gene-specific siRNA and conduct a search to make sure it lacks homology to any other gene.

B. Hairpin siRNA Template Oligonucleotide Design & Ordering

To use the pGPH1 siRNAi Expression Vector Kit, you will first need to design two single-stranded DNA oligonucleotides; one encoding the target shRNA ("top strand" oligo) and the other its complement ("bottom strand" oligo). You will then anneal the top and bottom strand oligos to generate a double-stranded oligonucleotide (ds oligo) suitable for cloning into the pGPH1 vector.

The design of the single-stranded oligonucleotides (ss oligos) is critical to the success of both the cloning procedure and ultimately, the RNAi analysis. General guidelines are provided in this section to help you choose the target sequence and to design the ss oligos. Note however, that simply following these guidelines does not guarantee that the shRNA will be effective in knocking down the target gene. For a given target gene, you may need to generate and screen multiple shRNA sequences to identify one that is active in gene knockdown studies.

Oligonucleotide design

Two complementary oligonucleotides must be synthesized, annealed, and ligated into pGPH1 for each siRNA target site. Figure 3 on page 8 shows schematically how to convert siRNA target sites into oligonucleotide sequences for use in the pGPH1 vectors. The oligonucleotides encode a hairpin structure with a 19-mer stem derived from the mRNA target site. The loop of the hairpin siRNA is located close to the center of the oligonucleotides; a variety of loop sequences have been successfully used by researchers (Sui 2002, Lee 2002, Paddsion 2002, Brummelkamp 2002, Paul 2002), and we have observed no particular benefit in using one or another. The loop sequence shown in Figure 3, 5'-UUCAAGAGA-3', is one possible sequence. Near the end of the hairpin siRNA template is a 5–6 nucleotide poly(T) tract recognized as a termination signal by RNA pol III that will terminate siRNA synthesis. The 5' ends of the two oligonucleotides are noncomplementary and form the *Bbs* I and *Bam*H I restriction site overhangs that facilitate efficient directional cloning into the pGPH1 vectors. Just downstream of the *Bbs* I site, it is advantageous to have a G or an A residue because RNA pol III prefers to initiate transcription with a purine. For siRNA targets with a C or a U

residue at position 1 (the first nucleotide after the AA in the RNA target sequence), add an additional G (shown with an asterisk in Figure 3) to facilitate transcription of the siRNA by RNA pol III.

Synthesis of hairpin siRNA template oligonucleotides for ligation into pGPH1 vectors

Order a 1-2 OD scale synthesis of each oligonucleotide. Typically we use economical, desalted-only DNA oligonucleotides in this procedure. It is important, however, that the oligonucleotides are mostly full-length. Choose a supplier that is reliable in terms of oligonucleotide sequence, length, and purity.

Figure 3. Hairpin siRNA Template Design



* Include an additional GC base pair at this position ***only*** if the downstream base on the top strand (the +1 position of the siRNA) is a Tor a C; if the +1 position is a G or an A, as it is in this example sequence, do not include it. The purpose of this additional base pair is to provide a G or an A residue as the first nucleotide of the siRNA transcript because RNA pol III prefers to initiate transcription with a purine, thus it helps to facilitate efficient transcription. Note, this additional nucleotide will not be complementary to either the target mRNA or the antisense strand of the hairpin siRNA. This extra nucleotide in the sense strand appears to have no effect on the activity of the hairpin siRNA.

III. Using the pGPH1 siRNA Expression Vector

A. Cloning Hairpin siRNA Inserts into pGPH1

1. Prepare a 1 µg/µl solution of each oligonucleotide

a. Dissolve the hairpin siRNA template oligonucleotides in approximately 100 µl of nuclease-free water.

b. Dilute 1 µl of each oligonucleotide 1:100 to 1:1000 in TE (10 mM Tris, 1 mM EDTA) and determine the absorbance at 260 nm. Calculate the concentration (in µg/ml) of the hairpin siRNA oligonucleotides by multiplying the A260 by the dilution factor and then by the extinction coefficient (~33 µg/ml).

c. Dilute the oligonucleotides to approximately 100 µM.

2. Anneal the siRNA template oligonucleotides

a. Assemble the 50 µl annealing mixture as follows:

Amount	Component
5 µl	10XshDNA Annealing Solution
5 µl	sense siRNA template oligonucleotide (100 uM)
5 µl	antisense siRNA template oligonucleotide (100 uM)
35 µl	ddH_2O

b. Heat the mixture to 95°C for 3 min, then turn off the heater and cool to room temperature slowly.

c. The annealed siRNA template insert can either be ligated into a pGPH1 vector or stored at –20°C for future ligation.

3. Ligate annealed siRNA template insert into pGPH1

a. Dilute the annealed siRNA template insert with nuclease-free water for a final concentration of 20 nM.

b. Set up two 10 µl ligation reactions; a plus-insert ligation, and the minus-insert negative control. To each tube, add the following reagents:

plus-insert	minus-insert	Component
1 µl	---	diluted annealed siRNA insert (from step 3.a.1 above)
---	1 µl	1X shDNA Annealing Solution
6.5 µl	6.5 µl	nuclease-free water
1 µl	1 µl	10X T4 DNA Ligase Buffer
1 µl	1 µl	PGPH1 vector
0.5 µl	0.5 µl	T4 DNA ligase (5 U/µl)

c. Incubate for 1–3 hr at room temp (the reactions can be incubated overnight at 16°C if very high ligation efficiency is required).
The recommended incubation time and temperature for ligation reactions varies widely among different sources of T4 DNA ligase. Follow the recommendation provided by the manufacturer of your DNA ligase, if using other source enzymes.

4. Transform *E. coli* with the ligation products

a. Transform an aliquot of cells with the plus- ligation products, and transform a second aliquot with the minus- ligation products. Use an appropriate amount of ligation product according to how the competent cells were prepared and the transformation method. (For chemically competent cells, we routinely transform with 3 µl of the ligation reaction.)

b. Plate the transformed cells on LB plates containing 50–200 µg/ml ampicillin or carbenicillin and grow overnight at 37°C. Generally it is a good idea to plate 2–3 different amounts of transformed cells so that at least one of the plates will have distinct colonies. ***Always*** include a non-transformed competent cell control: this negative control is a culture of your competent cells plated at the same density as your transformed cells.

c. Examine each plate and evaluate the number of colonies promptly after overnight growth at 37°C (or store the plates at 4°C until they are evaluated).

5. Expected results

Non-transformed control culture:

The non-transformed control culture should yield no colonies (indicating that the ampicillin or carbenicillin in the culture medium is effective at inhibiting the growth of *E. coli* that do not contain the pGPH1 vector)

Plus- and minus- ligation transformations

Identify the dilution of plus- and minus- ligation transformations that yield well-spaced (countable) colonies, and count the colonies on those plates. The minus- ligation will probably result in some ampicillin resistant colonies (background), but ***the plus- ligation should yield 2-10 fold more colonies than the minus- ligation***. (Remember to take the dilution into account when calculating the proportion of background colonies.)

6. Identify clones with the siRNA template insert

a. Pick clones, isolate plasmid DNA.
b. Digest the plasmid with *Bam*H I and *Eco*R I (*Hind* III and *Pst* I may also be chosen.), the recombinant plasmid containing the shDNA insert should be cut by *Bam*H I and uncut by *Eco*R I (or *Hind* III and *Pst* I)
c. Sequence with the primers shown below to verify that the clone contains the insert, and that it is the desired sequence. The entire pGPH1 sequence is provided in the Appendix part.

Primers used for pGPH1 sequence

Primer Name	Direction	Sequence
H1 sequencing primer	Forward	5'-GGA CTA TCA TAT GCT TAC CG-3'
T7 sequencing primer	Forward	5'-TAA TAC GAC TCA CTA TAG GG-3'
T3 sequencing primer	Reverse	5'-ATT AAC CCT CAC TAA AGG GAA-3'

7. Purify pGPH1 plasmid for transfection

pGPH1 plasmid preparations must be free of salts, proteins, and other contaminants to ensure efficient transfection. We routinely purify using commercially available plasmid purification products.

B. Transfecting pGPH1 into Mammalian Cells

We recommend using GenePharma's RNAi-Mate transfection reagent (Cat.No. C-01) to deliver pGPH1 plasmids into mammalian cells with high efficiency and minimal toxicity. Follow the instructions for using RNAi-Mate provided with the product. RNAi-Mate is a proprietary formulation of polyamines that can be used in the presence or absence of serum in the culture medium. It is suitable for the transfection of a wide variety of cell types.

IV. Troubleshooting

A. Positive Control Ligation

1. Description of the GAPDH Control Insert

The GAPDH Control Insert (200 nM) is a double-stranded DNA fragment with *Bam*H I and *Bbs* I sticky ends surrounding an siRNA template that targets the GAPDH mRNA. The sequence of the GAPDH Control Insert is perfectly complementary to a region of human GAPDH mRNA. The siRNA expressed from this template sequence has been shown to effectively induce silencing of GAPDH in human cell lines. The GAPDH Control Insert is provided as a control for the ligation reaction.

2. Ligation instructions

a. Dilute 2 µl of the GAPDH Control Insert with 18 µl nuclease-free water for a final concentration of 20 nM.
b. Ligate 1 µl of the GAPDH Control Insert into the pGPH1 vectors using the standard protocol beginning with step III.A.3 on page 10.

3. Expected result of the positive control ligation and *E. coli* transformation

If the ligation reaction and subsequent *E. coli* transformation procedure are functioning properly, then the ligation reaction with the GAPDH Control Insert (the plus-insert reaction) should provide 2–10 times as many colonies as the minus-insert ligation reaction.

B. Using the Positive and Negative Controls

pGPH1 Negative Control

The pGPH1 Negative Control plasmid supplied with the kit is a circular plasmid encoding a hairpin siRNA whose sequence is not found in the mouse, human, or rat genome databases. It is provided ready-to-transfect at 0.5 µg/µl and can be used to control for the effects of introducing the pGPH1 plasmid into cells. Cells transfected with the pGPH1 plasmid expressing your target-specific siRNA should be compared to cells transfected with the corresponding pGPH1 Negative Control.

For any RNAi experiment, it is important to include a culture that is transfected with a negative control plasmid as a basis for analysis of gene knockdown. The optimal negative control insert for expression analysis in a gene silencing experiment is the scrambled sequence of your gene specific siRNA.

Positive Control construct containing the GAPDH Control Insert

The product of the positive control ligation (described in section IV.A on page 12) is a pGPH1 plasmid containing an siRNA template targeting GAPDH. This construct can be used to optimize the pGPH1 transfection procedure. Use pGPH1-GAPDH and the pGPH1 Negative Control to transfect cells, and monitor cell viability and gene silencing of GAPDH to identify optimal transfection conditions.

When successfully transfected and expressed, the GAPDH siRNA reduces both the mRNA and protein levels of GAPDH in human cell lines. This slows the growth rate of the cells and reduces the rate of cell proliferation of most cell types. To assess whether siRNA-mediated gene silencing is occurring, levels of GAPDH RNA, levels of GAPDH protein, and/or cell proliferation can be monitored.

Any of the following assays for assessing siRNA-mediated reduction in GAPDH gene expression can be used:

a. **Quantitate mRNA levels by Northern analysis or RT-PCR.**

GAPDH mRNA levels are typically reduced 50–90% 48 hr after transfection.

b. **Analyze protein levels by Western blot, immunohistochemistry, or immunofluorescence.**

GAPDH protein levels are typically reduced 50–90% 48 hr after transfection.

c. **Look for a reduction in cell proliferation caused by GAPDH knock down.**

Although it is less direct than looking at GAPDH mRNA or protein levels, a reduction in GAPDH activity can be assessed by measuring cell proliferation. Depending on cell type, there should be a >40% reduction in cell number 48–72 hours after transfection.

C. Low *E. coli* Transformation Efficiency

1. Low quality competent cells

Cells could either be nonviable or exhibit low transformation competency. This can be tested by transforming a circular plasmid that has been used successfully in the past.

2. Poor ligation efficiency

If the ligation reaction (section III.A.3 on page 10) is inefficient, then there will be relatively few plasmids to transform. Possible causes of poor ligation efficiency include:

a. The concentration of the annealed siRNA template insert is lower than expected.

Evaluate ~5 µl of the insert DNA (from step A.2.c on page 9) using a 12% native polyacrylamide gel and compare its ethidium bromide staining to bands from a molecular weight marker or another standard of known concentration.

b. The ligase or ligase reaction buffer have become inactive.

Test your ligation components using another vector and insert or replace your ligation components and retry the siRNA insert cloning.

c. One or both of the hairpin siRNA template oligonucleotides have high levels of non-full-length products.

The size of oligonucleotides can be evaluated on an 12% native polyacrylamide gel.

d. The oligonucleotide annealing reaction was ineffective.

A low concentration of one of the oligonucleotides or incomplete denaturation of individual oligonucleotides could have reduced the relative amount of dsDNAs.

Compare the annealed siRNA template insert to each of the single-stranded oligonucleotides using native 8–12% polyacrylamide gel electrophoresis. If the annealed siRNA template insert has bands corresponding to the single-stranded oligonucleotides, then adjusting the concentrations of the single-stranded DNA molecules and heat-denaturing at a higher temperature during siRNA insert preparation (step A.2.b on page 9) might improve the percentage of dsDNA products. Alternatively, in some cases, gel purifying the band corresponding to annealed insert may result in better ligation.

e. Ligation inhibitors in the oligonucleotide preparations

EDTA and high concentrations of salts or other small molecules can inhibit ligation efficiency. Ethanol precipitate the oligonucleotides prior to using them in the cloning procedure (either before or after annealing).

f. Incompatible ends on the insert

Verify that the sequences of the hairpin siRNA template oligonucleotides include 5' *Bbs* 1 and 3' *Bam*H I overhanging sequences for cloning (see

Figure 3 on page 8).

3. Too much antibiotic or the wrong antibiotic in the media

The plates used for cloning should contain 50–200 µg/ml ampicillin or carbenicillin. Carbenicillin remains active in plates for longer than ampicillin.

4. Cells were handled poorly

Competent cells tend to be fragile, so handle them gently throughout the transformation and plating process.

D. Equal Numbers of E. coli Colonies from Minus- and Plus-insert Ligation Transformations

1. Ligation efficiency for the siRNA insert is low

See section C.2 on page 14.

2. The concentration or activity of the ampicillin is too low or high

If there are large numbers of clones derived from both ligations, then confirm that the ampicillin is active and at 50–200 µg/ml in the medium. If there are low numbers of clones for each, try transforming a plasmid with an ampicillin resistance gene (the pGPH1 Negative Control plasmid in the kit would be ideal) and confirm that the ampicillin concentration in the plates is not too high to allow the growth of transformed cells.

E. Poor Mammalian Cell Transformation Efficiency

If you suspect that pGPH1 transfection is suboptimal, consider using a mammalian expression plasmid containing a reporter gene such as GFP or β-galactosidase to troubleshoot transfection. Below are listed some general suggestions for troubleshooting mammalian cell transfection.

1. pGPH1 plasmid is not pure enough

The purity of the siRNA plasmid is vitally important for efficient transfection. Repurify plasmid preparation and transfect again.

2. Transfection protocol requires optimization

The ratio of transfection agent to cells to plasmid is important. Optimize these three components of the transfection protocol.

3. Ineffective transfection reagent

If you are using lipofection to facilitate transfection, then test a different transfection agent with your cells. Different cell types respond differently to different transfection reagents.

4. Ineffective siRNA vector

If you are using siRNA-induced gene knockdown to assess transfection efficiency, consider using a different siRNA. The GAPDH positive control insert supplied with the kit can be used to prepare a vector that has been shown to reduce GAPDH mRNA and protein levels in a variety of cell types.

V. Appendix

A. References

Brummelkamp TR, Bernards R, and Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. *Science* **296**: 550–553.

Byrom M, Pallotta V, Brown D, Ford L (2002) Visualizing siRNA in mammalian cells: fluorescence analysis of the RNAi effect. *Ambion TechNotes* **9.3**: 6–8.

Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* **411**: 494–498.

Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T (2001) Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate, *EMBO J* **20**(23): 6877–88.

Ilves H, Barske C, Junker U, Bohnlein E, Veres G (1996) Retroviral vectors designed for targeted expression of RNA polymerase III-driven transcripts: a comparative study. *Gene* **171**: 203–208.

Kunkel GR and Pederson T (1989) Transcription of a human U6 small nuclear RNA gene in vivo withstands deletion of intragenic sequences but not of an upstream TATATA box. *Nucleic Acids Res*. **17**: 7371–7379.

Lee NS, Dohjima T, Bauer G, Li H, Li M-J, Ehsani A, Salvaterra P, Rossi J (2001) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. *Nature Biotechnology* **19**: 500–505.

Miyagishi M & Taira K (2002) U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. *Nature Biotechnology* **20**: 497–500.

Myslinski E, Ame JC, Krol A, Carbon P (2001) An unusually compact external promoter for RNA polymerase III transcription of the human H1RNA gene. *Nucleic Acids Res.* **29**: 2502–9.

Paddison PJ, Caudy AA, Bernstein E, Hannon GJ and Conklin DS (2002) Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. *Genes & Development* **16**: 948–958.

Paul CP, Good PD, Winer I, Engelke DR (2002) Effective expression of small interfering RNA in human cells. *Nature Biotechnology* **20**: 505–508.

Sui G, Soohoo C, Affar EB, Gay F, Shi Y, Forrester WC, and Shi Y (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. *Proc Natl Acad Sci USA* **99(8)**: 5515–5520.

B. pGPH1 siRNA Expression Kit Specifications

Kit Components and Storage

E-01	F-01	Component
20 µl		pGPH1 (circular) (50 ng/ul)
	20µl	pGPH1 (linearized) (50 ng/ul)
10 µl	10 µl	pGPH1 Negative control (0.5 µg/µl)
10 µl	10 µl	GAPDH Control Insert (20 nM)
0.5 ml	0.5 ml	10×shDNA Annealing Solution

Store the pGPH1 siRNA Expression Kit at –20°C in a non-frost-free freezer (if desired the 1X DNA Annealing Solution can be stored at room temperature). Properly stored kits are guaranteed for 6 months from the date received.

C. Quality Control

Functional testing

The pGPH1 siRNA expression vector is ligated with the GAPDH Control Insert according to the instructions in this booklet. Ligation efficiency is then determined.

Nuclease testing

Each component is tested in GenePharma's rigorous nuclease assays.

RNase activity

None detected after incubation with ^{32}P-labeled RNA; analyzed by PAGE.

Non-specific endonuclease/nickase activity

None detected after incubation with supercoiled plasmid DNA; analyzed on 1% agarose.

Exonuclease activity

None detected after incubation with 32P-labeled *Sau*3A fragments of pUC19; analyzed by PAGE.

D. Map of pGPH1



Feature	Nucleotide Position
f1 (–) origin of ss-DNA replication	21-327
HH1 promoter	653-888
T7 promoter binding site	625-648
T3 promoter binding site	998-1018
pUC origin of replication	1385-2051
Ampicillin resistance (*bla*) ORF	2203-3059

E. pGPH1 Multiple Cloning Site Region

pGPH1 Multiple Cloning Site Region

(sequence shown 598-1089)

TTGTAAAACGACGGCCAGTGAGCGCGCGTAATACGACTCACTATAGGGCGAATTGGGTACCAATTC

M13-20 primer binding site T7 primer binding site

GAACGCTGACGTCATCAACCCGCTCCAAGGAATCGCGGGCCCAGTGTCACTAGGCGGGAACAC
CCAGCGCGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCAA
TATTTGCATGTCGCTATGTGTTCTGGGAAATCACCATAAACGTGAAATGTCTTTGGATTTGGGAAT

U6 promoter primer *Bam*H I

CTTATAAGTTCTGTATGAGACCACTCTT CACCGTGTCTTC..... G GATCCACTAG
GAATATTCAAGACATACTCTGGTGAGAAGTGG CACAGAAG.....CCTAG GTGATC

Bbs I

TTCTAGAGCGGCCGCCACCGCGGTGGAGCTCCAGCTTTTGTTCCCTTTAGTGAGGG

T3 primer binding site

TTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCC

M13 Reverse primer binding site

F. Sequence of pGPH1

The Sequence of pGPH1 plasmid (3187 bp in length)

```
      CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 1
      CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC 51
101     TTTCTTCCCT TCCTTTCTCG CCACGTTCGC CGGCTTTCCC CGTCAAGCTC
151     TAAATCGGGG GCTCCCTTTA GGGTTCCGAT TTAGTGCTTT ACGGCACCTC
201     GACCCCAAAA AACTTGATTA GGGTGATGGT TCACGTAGTG GGCCATCGCC
251     CTGATAGACG GTTTTTCGCC CTTTGACGTT GGAGTCCACG TTCTTTAATA
301     GTGGACTCTT GTTCCAAACT GGAACAACAC TCAACCCTAT CTCGGTCTAT
351     TCTTTTGATT TATAAGGGAT TTTGCCGATT TCGGCCTATT GGTTAAAAAA
401     TGAGCTGATT TAACAAAAAT TTAACGCGAA TTTTAACAAA ATATTAACGC
451     TTACAATTTC CATTCGCCAT TCAGGCTGCG CAACTGTTGG GAAGGGCGAT
501     CGGTGCGGGC CTCTTCGCTA TTACGCCAGC TGGCGAAAGG GGGATGTGCT
551     GCAAGGCGAT TAAGTTGGGT AACGCCAGGG TTTTCCCAGT CACGACGTTG
601     TAAAACGACG GCCAGTGAGC GCGCGTAATA CGACTCACTA TAGGGCGAAT
651     TGGGTACCAA TTCGAACGCT GACGTCATCA ACCCGCTCCA AGGAATCGCG
701     GGCCCAGTGT CACTAGGCGG GAACACCCAG CGCGCGTGCG CCCTGGCAGG
751     AAGATGGCTG TGAGGGACAG GGGAGTGGCG CCCTGCAATA TTTGCATGTC
801     GCTATGTGTT CTGGGAAATC ACCATAAACG TGAAATGTCT TTGGATTTGG
851     GAATCTTATA AGTTCTGTAT GAGACCACTC TTCACCGTGT CTTCTCGAGC
901     TCGAGGTCGA CGGTATCGAT AAGCTTGATA TCGAATTCCT GCAGCCCGGG
951     GGATCCACTA GTTCTAGAGC GGCCGCCACC GCGGTGGAGC TCCAGCTTTT
1001    GTTCCCTTTA GTGAGGGTTA ATTGCGCGCT TGGCGTAATC ATGGTCATAG
1051    CTGTTTCCTG TGTGAAATTG TTATCCGCTC ACAATTCCAC ACAACATACG
1101    AGCCGGAAGC ATAAAGTGTA AAGCCTGGGG TGCCTAATGA GTGAGCTAAC
1151    TCACATTAAT TGCGTTGCGC TCACTGCCCG CTTTCCAGTC GGGAAACCTG
1201    TCGTGCCAGC TGCATTAATG AATCGGCCAA CGCGCGGGGA GAGGCGGTTT
1251    GCGTATTGGG CGCTCTTCCG CTTCCTCGCT CACTGACTCG CTGCGCTCGG
1301    TCGTTCGGCT GCGGCGAGCG GTATCAGCTC ACTCAAAGGC GGTAATACGG
1351    TTATCCACAG AATCAGGGGA TAACGCAGGA AAGAACATGT GAGCAAAAGG
1401    CCAGCAAAAG GCCAGGAACC GTAAAAAGGC CGCGTTGCTG GCGTTTTTCC
1451    ATAGGCTCCG CCCCCCTGAC GAGCATCACA AAAATCGACG CTCAAGTCAG
1501    AGGTGGCGAA ACCCGACAGG ACTATAAAGA TACCAGGCGT TTCCCCCTGG
1551    AAGCTCCCTC GTGCGCTCTC CTGTTCCGAC CCTGCCGCTT ACCGGATACC
1601    TGTCCGCCTT TCTCCCTTCG GGAAGCGTGG CGCTTTCTCA TAGCTCACGC
1651    TGTAGGTATC TCAGTTCGGT GTAGGTCGTT CGCTCCAAGC TGGGCTGTGT
1701    GCACGAACCC CCCGTTCAGC CCGACCGCTG CGCCTTATCC GGTAACTATC
1751    GTCTTGAGTC CAACCCGGTA AGACACGACT TATCGCCACT GGCAGCAGCC
1801    ACTGGTAACA GGATTAGCAG AGCGAGGTAT GTAGGCGGTG CTACAGAGTT
```

```
AAGACACGAC TTATCGCCAC TGGCAGCAGC CACTGGTAAC AGGATTAGCA 1850
GAGCGAGGTA TGTAGGCGGT GCTACAGAGT TCTTGAAGTG GTGGCCTAAC 1900
TACGGCTACA CTAGAAGGAC AGTATTTGGT ATCTGCGCTC TGCTGAAGCC 1950
AGTTACCTTC GGAAAAAGAG TTGGTAGCTC TTGATCCGGC AAACAAACCA 2000
CCGCTGGTAG CGGTGGTTTT TTTGTTTGCA AGCAGCAGAT TACGCGCAGA 2050
AAAAAAGGAT CTCAAGAAGA TCCTTTGATC TTTTCTACGG GGTCTGACGC 2100
TCAGTGGAAC GAAAACTCAC GTTAAGGGAT TTTGGTCATG AGATTATCAA 2150
AAAGGATCTT CACCTAGATC CTTTTAAATT AAAAATGAAG TTTTAAATCA 2200
ATCTAAAGTA TATATGAGTA AACTTGGTCT GACAGTTACC AATGCTTAAT 2250
CAGTGAGGCA CCTATCTCAG CGATCTGTCT ATTTCGTTCA TCCATAGTTG 2300
CCTGACTCCC CGTCGTGTAG ATAACTACGA TACGGGAGGG CTTACCATCT 2350
GGCCCCAGTG CTGCAATGAT ACCGCGAGAC CCACGCTCAC CGGCTCCAGA 2400
TTTATCAGCA ATAAACCAGC CAGCCGGAAG GGCCGAGCGC AGAAGTGGTC 2450
CTGCAACTTT ATCCGCCTCC ATCCAGTCTA TTAATTGTTG CCGGGAAGCT 2500
AGAGTAAGTA GTTCGCCAGT TAATAGTTTG CGCAACGTTG TTGCCATTGC 2550
TACAGGCATC GTGGTGTCAC GCTCGTCGTT TGGTATGGCT TCATTCAGCT 2600
CCGGTTCCCA ACGATCAAGG CGAGTTACAT GATCCCCCAT GTTGTGCAAA 2650
AAAGCGGTTA GCTCCTTCGG TCCTCCGATC GTTGTCAGAA GTAAGTTGGC 2700
CGCAGTGTTA TCACTCATGG TTATGGCAGC ACTGCATAAT TCTCTTACTG 2750
TCATGCCATC CGTAAGATGC TTTTCTGTGA CTGGTGAGTA CTCAACCAAG 2800
TCATTCTGAG AATAGTGTAT GCGGCGACCG AGTTGCTCTT GCCCGGCGTC 2850
AATACGGGAT AATACCGCGC CACATAGCAG AACTTTAAAA GTGCTCATCA 2900
TTGGAAAACG TTCTTCGGGG CGAAAACTCT CAAGGATCTT ACCGCTGTTG 2950
AGATCCAGTT CGATGTAACC CACTCGTGCA CCCAACTGAT CTTCAGCATC 3000
TTTTACTTTC ACCAGCGTTT CTGGGTGAGC AAAAACAGGA AGGCAAAATG 3050
CCGCAAAAAA GGGAATAAGG GCGACACGGA AATGTTGAAT ACTCATACTC 3100
TTCCTTTTTC AATATTATTG AAGCATTTAT CAGGGTTATT GTCTCATGAG 3150
CGGATACATA TTTGAATGTA TTTAGAAAAA TAAACAAATA GGGGTTCCGC 3200
GCACATTTCC CCGAAAAGTG CCAC                             3250
```